In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed. The gene discussed is BRAF; the disease is thyroid gland carcinoma.